Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 393

1.

Fallopian Tube Lesions in Women at High Risk for Ovarian Cancer: A Multicenter Study.

Visvanathan K, Shaw P, May BJ, Bahadirli-Talbott A, Kaushiva A, Risch H, Narod S, Wang TL, Parkash V, Vang R, Levine DA, Soslow R, Kurman R, Shih IM.

Cancer Prev Res (Phila). 2018 Nov;11(11):697-706. doi: 10.1158/1940-6207.CAPR-18-0009. Epub 2018 Sep 19.

PMID:
30232083
2.

Human Papillomavirus Genotypes From Vaginal and Vulvar Intraepithelial Neoplasia in Females 15-26 Years of Age.

Garland SM, Joura EA, Ault KA, Bosch FX, Brown DR, Castellsagué X, Ferenczy A, Ferris DG, Giuliano AR, Hernandez-Avila M, Huh WK, Iversen OE, Kjaer SK, Kurman RJ, Luna J, Monsonego J, Muñoz N, Paavonen J, Pitisuttihum P, Ronnett BM, Steben M, Stoler MH, Wheeler CM, Wiley DJ, Perez G, Saah AJ, Luxembourg A, Li S, DiNubile MJ, Wagner M, Velicer C.

Obstet Gynecol. 2018 Aug;132(2):261-270. doi: 10.1097/AOG.0000000000002736.

PMID:
29995724
3.

Comprehensive Surgical Staging in Stage 1 Clear Cell and Endometrioid Ovarian Carcinomas: Is it Necessary?

Padhy RR, Savage J, Kurman RJ.

Int J Gynecol Pathol. 2018 May 10. doi: 10.1097/PGP.0000000000000521. [Epub ahead of print]

PMID:
29750701
4.

Evaluation of liquid from the Papanicolaou test and other liquid biopsies for the detection of endometrial and ovarian cancers.

Wang Y, Li L, Douville C, Cohen JD, Yen TT, Kinde I, Sundfelt K, Kjær SK, Hruban RH, Shih IM, Wang TL, Kurman RJ, Springer S, Ptak J, Popoli M, Schaefer J, Silliman N, Dobbyn L, Tanner EJ, Angarita A, Lycke M, Jochumsen K, Afsari B, Danilova L, Levine DA, Jardon K, Zeng X, Arseneau J, Fu L, Diaz LA Jr, Karchin R, Tomasetti C, Kinzler KW, Vogelstein B, Fader AN, Gilbert L, Papadopoulos N.

Sci Transl Med. 2018 Mar 21;10(433). pii: eaap8793. doi: 10.1126/scitranslmed.aap8793.

PMID:
29563323
5.

High grade serous ovarian carcinomas originate in the fallopian tube.

Labidi-Galy SI, Papp E, Hallberg D, Niknafs N, Adleff V, Noe M, Bhattacharya R, Novak M, Jones S, Phallen J, Hruban CA, Hirsch MS, Lin DI, Schwartz L, Maire CL, Tille JC, Bowden M, Ayhan A, Wood LD, Scharpf RB, Kurman R, Wang TL, Shih IM, Karchin R, Drapkin R, Velculescu VE.

Nat Commun. 2017 Oct 23;8(1):1093. doi: 10.1038/s41467-017-00962-1.

6.

Molecular analysis of high-grade serous ovarian carcinoma with and without associated serous tubal intra-epithelial carcinoma.

Ducie J, Dao F, Considine M, Olvera N, Shaw PA, Kurman RJ, Shih IM, Soslow RA, Cope L, Levine DA.

Nat Commun. 2017 Oct 17;8(1):990. doi: 10.1038/s41467-017-01217-9.

7.

Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16-26 years: a randomised, double-blind trial.

Huh WK, Joura EA, Giuliano AR, Iversen OE, de Andrade RP, Ault KA, Bartholomew D, Cestero RM, Fedrizzi EN, Hirschberg AL, Mayrand MH, Ruiz-Sternberg AM, Stapleton JT, Wiley DJ, Ferenczy A, Kurman R, Ronnett BM, Stoler MH, Cuzick J, Garland SM, Kjaer SK, Bautista OM, Haupt R, Moeller E, Ritter M, Roberts CC, Shields C, Luxembourg A.

Lancet. 2017 Nov 11;390(10108):2143-2159. doi: 10.1016/S0140-6736(17)31821-4. Epub 2017 Sep 5.

PMID:
28886907
8.

Atypical Proliferative (Borderline) Serous Tumor in the Brain: A Case Report.

Xing D, Jenson EG, Zwick CA, Rodriguez FJ, Kurman RJ.

Int J Gynecol Pathol. 2018 Jan;37(1):52-56. doi: 10.1097/PGP.0000000000000389.

PMID:
28700421
9.

Long-term Behavior of Serous Borderline Tumors Subdivided Into Atypical Proliferative Tumors and Noninvasive Low-grade Carcinomas: A Population-based Clinicopathologic Study of 942 Cases.

Vang R, Hannibal CG, Junge J, Frederiksen K, Kjaer SK, Kurman RJ.

Am J Surg Pathol. 2017 Jun;41(6):725-737. doi: 10.1097/PAS.0000000000000824.

10.

Parity, infertility, oral contraceptives, and hormone replacement therapy and the risk of ovarian serous borderline tumors: A nationwide case-control study.

Rasmussen ELK, Hannibal CG, Dehlendorff C, Baandrup L, Junge J, Vang R, Kurman RJ, Kjaer SK.

Gynecol Oncol. 2017 Mar;144(3):571-576. doi: 10.1016/j.ygyno.2017.01.002. Epub 2017 Jan 17.

PMID:
28108026
11.

Steroid hormone synthesis by the ovarian stroma surrounding epithelial ovarian tumors: a potential mechanism in ovarian tumorigenesis.

Blanco LZ Jr, Kuhn E, Morrison JC, Bahadirli-Talbott A, Smith-Sehdev A, Kurman RJ.

Mod Pathol. 2017 Apr;30(4):563-576. doi: 10.1038/modpathol.2016.219. Epub 2017 Jan 6.

12.

A nationwide study of ovarian serous borderline tumors in Denmark 1978-2002. Risk of recurrence, and development of ovarian serous carcinoma.

Hannibal CG, Vang R, Junge J, Frederiksen K, Kurman RJ, Kjaer SK.

Gynecol Oncol. 2017 Jan;144(1):174-180. doi: 10.1016/j.ygyno.2016.11.007. Epub 2016 Nov 9.

13.

CCNE1 amplification and centrosome number abnormality in serous tubal intraepithelial carcinoma: further evidence supporting its role as a precursor of ovarian high-grade serous carcinoma.

Kuhn E, Wang TL, Doberstein K, Bahadirli-Talbott A, Ayhan A, Sehdev AS, Drapkin R, Kurman RJ, Shih IeM.

Mod Pathol. 2016 Oct;29(10):1254-61. doi: 10.1038/modpathol.2016.101. Epub 2016 Jul 22.

14.

Diagnostic potential of tumor DNA from ovarian cyst fluid.

Wang Y, Sundfeldt K, Mateoiu C, Shih IeM, Kurman RJ, Schaefer J, Silliman N, Kinde I, Springer S, Foote M, Kristjansdottir B, James N, Kinzler KW, Papadopoulos N, Diaz LA, Vogelstein B.

Elife. 2016 Jul 15;5. pii: e15175. doi: 10.7554/eLife.15175.

15.

PD-L1 Expression in Human Placentas and Gestational Trophoblastic Diseases.

Veras E, Kurman RJ, Wang TL, Shih IM.

Int J Gynecol Pathol. 2017 Mar;36(2):146-153. doi: 10.1097/PGP.0000000000000305.

16.

The Dualistic Model of Ovarian Carcinogenesis: Revisited, Revised, and Expanded.

Kurman RJ, Shih IeM.

Am J Pathol. 2016 Apr;186(4):733-47. doi: 10.1016/j.ajpath.2015.11.011. Review.

17.

Seromucinous Tumors of the Ovary. What's in a Name?

Kurman RJ, Shih IeM.

Int J Gynecol Pathol. 2016 Jan;35(1):78-81. doi: 10.1097/PGP.0000000000000266. Review.

18.

Molecular analysis of ovarian mucinous carcinoma reveals different cell of origins.

Wang Y, Schwartz LE, Anderson D, Lin MT, Haley L, Wu RC, Vang R, Shih IeM, Kurman RJ.

Oncotarget. 2015 Sep 8;6(26):22949-58.

19.

Molecular Alterations of TP53 are a Defining Feature of Ovarian High-Grade Serous Carcinoma: A Rereview of Cases Lacking TP53 Mutations in The Cancer Genome Atlas Ovarian Study.

Vang R, Levine DA, Soslow RA, Zaloudek C, Shih IeM, Kurman RJ.

Int J Gynecol Pathol. 2016 Jan;35(1):48-55. doi: 10.1097/PGP.0000000000000207.

20.

Clonality analysis of combined Brenner and mucinous tumours of the ovary reveals their monoclonal origin.

Wang Y, Wu RC, Shwartz LE, Haley L, Lin MT, Shih IeM, Kurman RJ.

J Pathol. 2015 Oct;237(2):146-51. doi: 10.1002/path.4572. Epub 2015 Jul 23.

21.
22.

Two types of ovarian cortical inclusion cysts: proposed origin and possible role in ovarian serous carcinogenesis.

Banet N, Kurman RJ.

Int J Gynecol Pathol. 2015 Jan;34(1):3-8. doi: 10.1097/PGP.0000000000000120.

PMID:
25473746
23.

Characterization of the immune cell repertoire in the normal fallopian tube.

Ardighieri L, Lonardi S, Moratto D, Facchetti F, Shih IeM, Vermi W, Kurman RJ.

Int J Gynecol Pathol. 2014 Nov;33(6):581-91. doi: 10.1097/PGP.0000000000000095.

24.

Loss of ALDH1A1 expression is an early event in the pathogenesis of ovarian high-grade serous carcinoma.

Chui MH, Wang Y, Wu RC, Seidman J, Kurman RJ, Wang TL, Shih IeM.

Mod Pathol. 2015 Mar;28(3):437-45. doi: 10.1038/modpathol.2014.89. Epub 2014 Sep 12.

25.

BRAF mutation is associated with a specific cell type with features suggestive of senescence in ovarian serous borderline (atypical proliferative) tumors.

Zeppernick F, Ardighieri L, Hannibal CG, Vang R, Junge J, Kjaer SK, Zhang R, Kurman RJ, Shih IeM.

Am J Surg Pathol. 2014 Dec;38(12):1603-11. doi: 10.1097/PAS.0000000000000313. Erratum in: Am J Surg Pathol. 2015 Jul;39(7):1014.

26.

A nationwide study of serous "borderline" ovarian tumors in Denmark 1978-2002: centralized pathology review and overall survival compared with the general population.

Hannibal CG, Vang R, Junge J, Frederiksen K, Kjaerbye-Thygesen A, Andersen KK, Tabor A, Kurman RJ, Kjaer SK.

Gynecol Oncol. 2014 Aug;134(2):267-73. doi: 10.1016/j.ygyno.2014.06.002. Epub 2014 Jun 10.

27.
28.

A genetically engineered ovarian cancer mouse model based on fallopian tube transformation mimics human high-grade serous carcinoma development.

Sherman-Baust CA, Kuhn E, Valle BL, Shih IeM, Kurman RJ, Wang TL, Amano T, Ko MS, Miyoshi I, Araki Y, Lehrmann E, Zhang Y, Becker KG, Morin PJ.

J Pathol. 2014 Jul;233(3):228-37. doi: 10.1002/path.4353.

29.

Ki-67 index as an ancillary tool in the differential diagnosis of proliferative endometrial lesions with secretory change.

Gurda GT, Baras AS, Kurman RJ.

Int J Gynecol Pathol. 2014 Mar;33(2):114-9. doi: 10.1097/PGP.0000000000000092.

PMID:
24487464
30.

Evaluation of microinvasion and lymph node involvement in ovarian serous borderline/atypical proliferative serous tumors: a morphologic and immunohistochemical analysis of 37 cases.

Maniar KP, Wang Y, Visvanathan K, Shih IeM, Kurman RJ.

Am J Surg Pathol. 2014 Jun;38(6):743-55. doi: 10.1097/PAS.0000000000000155.

31.

Pathologic features associated with resolution of complex atypical hyperplasia and grade 1 endometrial adenocarcinoma after progestin therapy.

Gunderson CC, Dutta S, Fader AN, Maniar KP, Nasseri-Nik N, Bristow RE, Diaz-Montes TP, Palermo R, Kurman RJ.

Gynecol Oncol. 2014 Jan;132(1):33-7. doi: 10.1016/j.ygyno.2013.11.033. Epub 2013 Dec 4.

PMID:
24316307
32.

Mutational analysis of BRAF and KRAS in ovarian serous borderline (atypical proliferative) tumours and associated peritoneal implants.

Ardighieri L, Zeppernick F, Hannibal CG, Vang R, Cope L, Junge J, Kjaer SK, Kurman RJ, Shih IeM.

J Pathol. 2014 Jan;232(1):16-22. doi: 10.1002/path.4293.

33.

Origin and molecular pathogenesis of ovarian high-grade serous carcinoma.

Kurman RJ.

Ann Oncol. 2013 Dec;24 Suppl 10:x16-21. doi: 10.1093/annonc/mdt463. Review.

PMID:
24265397
34.

Ovarian Brenner tumour: a morphologic and immunohistochemical analysis suggesting an origin from fallopian tube epithelium.

Kuhn E, Ayhan A, Shih IeM, Seidman JD, Kurman RJ.

Eur J Cancer. 2013 Dec;49(18):3839-49. doi: 10.1016/j.ejca.2013.08.011. Epub 2013 Sep 5.

PMID:
24012099
35.

Origin and pathogenesis of pelvic (ovarian, tubal, and primary peritoneal) serous carcinoma.

Nik NN, Vang R, Shih IeM, Kurman RJ.

Annu Rev Pathol. 2014;9:27-45. doi: 10.1146/annurev-pathol-020712-163949. Epub 2013 Aug 5. Review.

PMID:
23937438
36.

The pathogenesis of atypical proliferative Brenner tumor: an immunohistochemical and molecular genetic analysis.

Kuhn E, Ayhan A, Shih IeM, Seidman JD, Kurman RJ.

Mod Pathol. 2014 Feb;27(2):231-7. doi: 10.1038/modpathol.2013.142. Epub 2013 Jul 26.

37.

Bokhman's dualistic model of endometrial carcinoma. Revisited.

Kurman RJ, Visvanathan K, Shih IeM.

Gynecol Oncol. 2013 May;129(2):271-2. doi: 10.1016/j.ygyno.2013.03.029. No abstract available.

PMID:
23582581
38.

Evaluation of DNA from the Papanicolaou test to detect ovarian and endometrial cancers.

Kinde I, Bettegowda C, Wang Y, Wu J, Agrawal N, Shih IeM, Kurman R, Dao F, Levine DA, Giuntoli R, Roden R, Eshleman JR, Carvalho JP, Marie SK, Papadopoulos N, Kinzler KW, Vogelstein B, Diaz LA Jr.

Sci Transl Med. 2013 Jan 9;5(167):167ra4. doi: 10.1126/scitranslmed.3004952.

39.

Fallopian tube precursors of ovarian low- and high-grade serous neoplasms.

Vang R, Shih IeM, Kurman RJ.

Histopathology. 2013 Jan;62(1):44-58. doi: 10.1111/his.12046. Review.

PMID:
23240669
40.

Trophoblastic disease.

Ngan HY, Kohorn EI, Cole LA, Kurman RJ, Kim SJ, Lurain JR, Seckl MJ, Sasaki S, Soper JT.

Int J Gynaecol Obstet. 2012 Oct;119 Suppl 2:S130-6. doi: 10.1016/S0020-7292(12)60026-5. No abstract available. Erratum in: Int J Gynaecol Obstet. 2014 Apr;125(1):93.

PMID:
22999504
41.

Diagnostic reproducibility of hydatidiform moles: ancillary techniques (p57 immunohistochemistry and molecular genotyping) improve morphologic diagnosis for both recently trained and experienced gynecologic pathologists.

Gupta M, Vang R, Yemelyanova AV, Kurman RJ, Li FR, Maambo EC, Murphy KM, DeScipio C, Thompson CB, Ronnett BM.

Am J Surg Pathol. 2012 Dec;36(12):1747-60. doi: 10.1097/PAS.0b013e31825ea736.

42.

Loss of ARID1A expression is an early molecular event in tumor progression from ovarian endometriotic cyst to clear cell and endometrioid carcinoma.

Ayhan A, Mao TL, Seckin T, Wu CH, Guan B, Ogawa H, Futagami M, Mizukami H, Yokoyama Y, Kurman RJ, Shih IeM.

Int J Gynecol Cancer. 2012 Oct;22(8):1310-5.

43.

Identification of molecular pathway aberrations in uterine serous carcinoma by genome-wide analyses.

Kuhn E, Wu RC, Guan B, Wu G, Zhang J, Wang Y, Song L, Yuan X, Wei L, Roden RB, Kuo KT, Nakayama K, Clarke B, Shaw P, Olvera N, Kurman RJ, Levine DA, Wang TL, Shih IeM.

J Natl Cancer Inst. 2012 Oct 3;104(19):1503-13. doi: 10.1093/jnci/djs345. Epub 2012 Aug 23.

44.

The diagnostic and biological implications of laminin expression in serous tubal intraepithelial carcinoma.

Kuhn E, Kurman RJ, Soslow RA, Han G, Sehdev AS, Morin PJ, Wang TL, Shih IeM.

Am J Surg Pathol. 2012 Dec;36(12):1826-34. doi: 10.1097/PAS.0b013e31825ec07a.

45.

Ki-67 labeling index as an adjunct in the diagnosis of serous tubal intraepithelial carcinoma.

Kuhn E, Kurman RJ, Sehdev AS, Shih IeM.

Int J Gynecol Pathol. 2012 Sep;31(5):416-22. doi: 10.1097/PGP.0b013e31824cbeb4.

46.

Endocervical-type mucinous borderline tumors are related to endometrioid tumors based on mutation and loss of expression of ARID1A.

Wu CH, Mao TL, Vang R, Ayhan A, Wang TL, Kurman RJ, Shih IeM.

Int J Gynecol Pathol. 2012 Jul;31(4):297-303. doi: 10.1097/PGP.0b013e31823f8482.

47.

Ovarian Cancer Is an Imported Disease: Fact or Fiction?

Kuhn E, Kurman RJ, Shih IM.

Curr Obstet Gynecol Rep. 2012 Mar;1(1):1-9.

48.

Validation of an algorithm for the diagnosis of serous tubal intraepithelial carcinoma.

Vang R, Visvanathan K, Gross A, Maambo E, Gupta M, Kuhn E, Li RF, Ronnett BM, Seidman JD, Yemelyanova A, Shih IeM, Shaw PA, Soslow RA, Kurman RJ.

Int J Gynecol Pathol. 2012 May;31(3):243-53. doi: 10.1097/PGP.0b013e31823b8831.

49.

A binary histologic grading system for ovarian serous carcinoma is an independent prognostic factor: a population-based study of 4317 women diagnosed in Denmark 1978-2006.

Hannibal CG, Vang R, Junge J, Kjaerbye-Thygesen A, Kurman RJ, Kjaer SK.

Gynecol Oncol. 2012 Jun;125(3):655-60. doi: 10.1016/j.ygyno.2012.02.028. Epub 2012 Feb 24.

50.

Diagnostic reproducibility of hydatidiform moles: ancillary techniques (p57 immunohistochemistry and molecular genotyping) improve morphologic diagnosis.

Vang R, Gupta M, Wu LS, Yemelyanova AV, Kurman RJ, Murphy KM, Descipio C, Ronnett BM.

Am J Surg Pathol. 2012 Mar;36(3):443-53. doi: 10.1097/PAS.0b013e31823b13fe.

Supplemental Content

Loading ...
Support Center